Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching

Ephraim J. Fuchs, MD MBA, Shannon R McCurdy, MD, Scott R. Solomon, MD, Tao Wang, PhD, Michelle Kuxhausen, MS, Yvette L Kasamon, MD, MHD Monzr Al Malki, MD, Shahinaz Gadalla, MD PhD, Sophie Paczesny, MDPhD, Steven GE Marsh, BSc, PhD ARCS, Bronwen E. Shaw, PhD MRCP, FRCPath, Stephen R. Spellman, MS, Stephanie J. Lee, MDMPH, Effie Petersdorf, MD

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-140433

Published: 2020

Journal Articles

Solid Organ Transplant Rejection Associated with the Use of the Immunomodulatory Drugs (IMIDs)

Michelle Nadeau Nguyen, Afrouz Nayernama, PharmD, Steven Christopher Jones, PharmD, Yvette L. Kasamon, MD, Peter E. Waldron, MD

Blood (2019) 134 (Supplement_1): 2189.

https://doi.org/10.1182/blood-2019-123146

Published: 2019

Journal Articles

Nonmyeloablative (NMA), HLA-Haploidentical (Haplo) Blood or Marrow Transplantation (BMT) from Non-First-Degree Related Donors Has Similar Outcomes to First-Degree Related BMT

Hany Elmariah, MDMS, Yvette L Kasamon, MD, Marianna Zahurak, MS, Noah Tucker, CCRC, Gary Rosner, ScD, F Javier Bolanos-Meade, MD, Ravi Varadhan, PhD, Ephraim J. Fuchs, MD MBA, Amy E. DeZern, MD, Leo Luznik, MD, Richard J. Jones, PhD, Richard F Ambinder, MD

Blood (2017) 130 (Supplement 1): 3304.

https://doi.org/10.1182/blood.V130.Suppl_1.3304.3304

Published: 2017

Journal Articles

Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy)

Shannon R. McCurdy, Christopher G. Kanakry, Yvette L. Kasamon, MD, Javier Bolanos Meade, MD, Hua-Ling Tsai, Margaret M. Showel, Jennifer A. Kanakry, Heather J. Symons, MD MHS, Gary L. Rosner, Sc.D, Ephraim J. Fuchs, Richard J. Jones, Leo Luznik, MD

Blood (2014) 124 (21): 730.

https://doi.org/10.1182/blood.V124.21.730.730

Published: 2014

Journal Articles

HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Heather Symons, MD, MHS, Allen R. Chen, MD, PhD, MHS, M. Sue Leffell, PhD, Marianna Zahurak, M.S., Kathy Schultz, Heather Karaszkiewicz, Leo Luznik, MD, Javier Bolanos Meade, MD, Yvette L. Kasamon, MD, Lode J. Swinnen, MD, Douglas Edward Gladstone, MD, Richard J. Jones, MD, Ephraim Fuchs, MD, MBA

Blood (2010) 116 (21): 2362.

https://doi.org/10.1182/blood.V116.21.2362.2362

Published: 2010

Journal Articles

K562/GM-CSF Vaccination Reduces Tumor Burden, Including Achieving Molecular Remissions, in Chronic Myeloid Leukemia (CML) Patients with Residual Disease on Imatinib Mesylate (IM).

B. Douglas Smith, MD, Yvette L. Kasamon, MD, Carole B. Miller, MD, Christina Chia, MD, Kathleen Murphy, PhD, Jeanne Kowalski, PhD, Irena Tartakovsky, MS, Barbara Biedrzycki, AOCN/CRNP, Richard J. Jones, MD, Kristen Hege, MD, Hyam I. Levitsky, MD

Blood (2005) 106 (11): 2858.

https://doi.org/10.1182/blood.V106.11.2858.2858

Published: 2005

Journal Articles

Outcomes of Autologous and Allogeneic BMT for Mantle Cell Lymphoma.

Yvette L. Kasamon, MD, Richard J. Jones, MD, Louis F. Diehl, MD, Hassan Nayer, MD, Michael J. Borowitz, MD, Elizabeth Garrett-Mayer, PhD, Richard F. Ambinder, MD, PhD, Ross A. Abrams, MD, Zhe Zhang, MS, Ian W. Flinn, MD, PhD

Blood (2004) 104 (11): 901.

https://doi.org/10.1182/blood.V104.11.901.901

Published: 2004

NARROW

Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching

Solid Organ Transplant Rejection Associated with the Use of the Immunomodulatory Drugs (IMIDs)

Nonmyeloablative (NMA), HLA-Haploidentical (Haplo) Blood or Marrow Transplantation (BMT) from Non-First-Degree Related Donors Has Similar Outcomes to First-Degree Related BMT

Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy)

HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

K562/GM-CSF Vaccination Reduces Tumor Burden, Including Achieving Molecular Remissions, in Chronic Myeloid Leukemia (CML) Patients with Residual Disease on Imatinib Mesylate (IM).

Outcomes of Autologous and Allogeneic BMT for Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching

Solid Organ Transplant Rejection Associated with the Use of the Immunomodulatory Drugs (IMIDs)

Nonmyeloablative (NMA), HLA-Haploidentical (Haplo) Blood or Marrow Transplantation (BMT) from Non-First-Degree Related Donors Has Similar Outcomes to First-Degree Related BMT

Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy)

HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

K562/GM-CSF Vaccination Reduces Tumor Burden, Including Achieving Molecular Remissions, in Chronic Myeloid Leukemia (CML) Patients with Residual Disease on Imatinib Mesylate (IM).

Outcomes of Autologous and Allogeneic BMT for Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only